Cargando…

Pharmacokinetics of gentamicin eluted from a regenerating bone graft substitute: In vitro and clinical release studies

OBJECTIVES: Deep bone and joint infections (DBJI) are directly intertwined with health, demographic change towards an elderly population, and wellbeing. The elderly human population is more prone to acquire infections, and the consequences such as pain, reduced quality of life, morbidity, absence fr...

Descripción completa

Detalles Bibliográficos
Autores principales: Stravinskas, M., Horstmann, P., Ferguson, J., Hettwer, W., Nilsson, M., Tarasevicius, S., Petersen, M. M., McNally, M. A., Lidgren, L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5047051/
https://www.ncbi.nlm.nih.gov/pubmed/27678329
http://dx.doi.org/10.1302/2046-3758.59.BJR-2016-0108.R1
_version_ 1782457386006478848
author Stravinskas, M.
Horstmann, P.
Ferguson, J.
Hettwer, W.
Nilsson, M.
Tarasevicius, S.
Petersen, M. M.
McNally, M. A.
Lidgren, L.
author_facet Stravinskas, M.
Horstmann, P.
Ferguson, J.
Hettwer, W.
Nilsson, M.
Tarasevicius, S.
Petersen, M. M.
McNally, M. A.
Lidgren, L.
author_sort Stravinskas, M.
collection PubMed
description OBJECTIVES: Deep bone and joint infections (DBJI) are directly intertwined with health, demographic change towards an elderly population, and wellbeing. The elderly human population is more prone to acquire infections, and the consequences such as pain, reduced quality of life, morbidity, absence from work and premature retirement due to disability place significant burdens on already strained healthcare systems and societal budgets. DBJIs are less responsive to systemic antibiotics because of poor vascular perfusion in necrotic bone, large bone defects and persistent biofilm-based infection. Emerging bacterial resistance poses a major threat and new innovative treatment modalities are urgently needed to curb its current trajectory. MATERIALS AND METHODS: We present a new biphasic ceramic bone substitute consisting of hydroxyapatite and calcium sulphate for local antibiotic delivery in combination with bone regeneration. Gentamicin release was measured in four setups: 1) in vitro elution in Ringer’s solution; 2) local elution in patients treated for trochanteric hip fractures or uncemented hip revisions; 3) local elution in patients treated with a bone tumour resection; and 4) local elution in patients treated surgically for chronic corticomedullary osteomyelitis. RESULTS: The release pattern in vitro was comparable with the obtained release in the patient studies. No recurrence was detected in the osteomyelitis group at latest follow-up (minimum 1.5 years). CONCLUSIONS: This new biphasic bone substitute containing antibiotics provides safe prevention of bone infections in a range of clinical situations. The in vitro test method predicts the in vivo performance and makes it a reliable tool in the development of future antibiotic-eluting bone-regenerating materials. Cite this article: M. Stravinskas, P. Horstmann, J. Ferguson, W. Hettwer, M. Nilsson, S. Tarasevicius, M. M. Petersen, M. A. McNally, L. Lidgren. Pharmacokinetics of gentamicin eluted from a regenerating bone graft substitute: In vitro and clinical release studies. Bone Joint Res 2016;5:427–435. DOI: 10.1302/2046-3758.59.BJR-2016-0108.R1.
format Online
Article
Text
id pubmed-5047051
institution National Center for Biotechnology Information
language English
publishDate 2016
record_format MEDLINE/PubMed
spelling pubmed-50470512016-10-05 Pharmacokinetics of gentamicin eluted from a regenerating bone graft substitute: In vitro and clinical release studies Stravinskas, M. Horstmann, P. Ferguson, J. Hettwer, W. Nilsson, M. Tarasevicius, S. Petersen, M. M. McNally, M. A. Lidgren, L. Bone Joint Res Trauma OBJECTIVES: Deep bone and joint infections (DBJI) are directly intertwined with health, demographic change towards an elderly population, and wellbeing. The elderly human population is more prone to acquire infections, and the consequences such as pain, reduced quality of life, morbidity, absence from work and premature retirement due to disability place significant burdens on already strained healthcare systems and societal budgets. DBJIs are less responsive to systemic antibiotics because of poor vascular perfusion in necrotic bone, large bone defects and persistent biofilm-based infection. Emerging bacterial resistance poses a major threat and new innovative treatment modalities are urgently needed to curb its current trajectory. MATERIALS AND METHODS: We present a new biphasic ceramic bone substitute consisting of hydroxyapatite and calcium sulphate for local antibiotic delivery in combination with bone regeneration. Gentamicin release was measured in four setups: 1) in vitro elution in Ringer’s solution; 2) local elution in patients treated for trochanteric hip fractures or uncemented hip revisions; 3) local elution in patients treated with a bone tumour resection; and 4) local elution in patients treated surgically for chronic corticomedullary osteomyelitis. RESULTS: The release pattern in vitro was comparable with the obtained release in the patient studies. No recurrence was detected in the osteomyelitis group at latest follow-up (minimum 1.5 years). CONCLUSIONS: This new biphasic bone substitute containing antibiotics provides safe prevention of bone infections in a range of clinical situations. The in vitro test method predicts the in vivo performance and makes it a reliable tool in the development of future antibiotic-eluting bone-regenerating materials. Cite this article: M. Stravinskas, P. Horstmann, J. Ferguson, W. Hettwer, M. Nilsson, S. Tarasevicius, M. M. Petersen, M. A. McNally, L. Lidgren. Pharmacokinetics of gentamicin eluted from a regenerating bone graft substitute: In vitro and clinical release studies. Bone Joint Res 2016;5:427–435. DOI: 10.1302/2046-3758.59.BJR-2016-0108.R1. 2016-09-29 /pmc/articles/PMC5047051/ /pubmed/27678329 http://dx.doi.org/10.1302/2046-3758.59.BJR-2016-0108.R1 Text en © 2016 Nilsson et al. This is an open-access article distributed under the terms of the Creative Commons Attributions licence (CC-BY-NC), which permits unrestricted use, distribution, and reproduction in any medium, but not for commercial gain, provided the original author and source are credited.
spellingShingle Trauma
Stravinskas, M.
Horstmann, P.
Ferguson, J.
Hettwer, W.
Nilsson, M.
Tarasevicius, S.
Petersen, M. M.
McNally, M. A.
Lidgren, L.
Pharmacokinetics of gentamicin eluted from a regenerating bone graft substitute: In vitro and clinical release studies
title Pharmacokinetics of gentamicin eluted from a regenerating bone graft substitute: In vitro and clinical release studies
title_full Pharmacokinetics of gentamicin eluted from a regenerating bone graft substitute: In vitro and clinical release studies
title_fullStr Pharmacokinetics of gentamicin eluted from a regenerating bone graft substitute: In vitro and clinical release studies
title_full_unstemmed Pharmacokinetics of gentamicin eluted from a regenerating bone graft substitute: In vitro and clinical release studies
title_short Pharmacokinetics of gentamicin eluted from a regenerating bone graft substitute: In vitro and clinical release studies
title_sort pharmacokinetics of gentamicin eluted from a regenerating bone graft substitute: in vitro and clinical release studies
topic Trauma
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5047051/
https://www.ncbi.nlm.nih.gov/pubmed/27678329
http://dx.doi.org/10.1302/2046-3758.59.BJR-2016-0108.R1
work_keys_str_mv AT stravinskasm pharmacokineticsofgentamicinelutedfromaregeneratingbonegraftsubstituteinvitroandclinicalreleasestudies
AT horstmannp pharmacokineticsofgentamicinelutedfromaregeneratingbonegraftsubstituteinvitroandclinicalreleasestudies
AT fergusonj pharmacokineticsofgentamicinelutedfromaregeneratingbonegraftsubstituteinvitroandclinicalreleasestudies
AT hettwerw pharmacokineticsofgentamicinelutedfromaregeneratingbonegraftsubstituteinvitroandclinicalreleasestudies
AT nilssonm pharmacokineticsofgentamicinelutedfromaregeneratingbonegraftsubstituteinvitroandclinicalreleasestudies
AT taraseviciuss pharmacokineticsofgentamicinelutedfromaregeneratingbonegraftsubstituteinvitroandclinicalreleasestudies
AT petersenmm pharmacokineticsofgentamicinelutedfromaregeneratingbonegraftsubstituteinvitroandclinicalreleasestudies
AT mcnallyma pharmacokineticsofgentamicinelutedfromaregeneratingbonegraftsubstituteinvitroandclinicalreleasestudies
AT lidgrenl pharmacokineticsofgentamicinelutedfromaregeneratingbonegraftsubstituteinvitroandclinicalreleasestudies